NeoStem, Inc. (NeoStem) is a provider of cellular therapy products. The Company is engaged in the development of cell therapy products; it also provides development and manufacturing services. NeoStem’s research and clinical development activities are aimed at three therapeutic platforms: ischemic repair (CD34 Cell Program), immune modulation (T Regulatory Cell Program) and tissue regeneration (VSELTM Technology). The Company develops therapies to address ischemia through its CD34 Cell Program. The Company focuses on the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs, restoring their normal function. The Company’s AMR-001 is the product candidate in its CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) (AMI).